Did you have any side effects with this medicine?

 No   Yes 

• Dosage of Bedranol in details
• Bedranol interactions
• Bedranol reviews

Dosage of Bedranol in details

Bedranol Dosage

Generic name: Bedranol 60mg

Dosage form: capsule, extended release

See also:

• Bedranol Tablets
• Bedranol XL capsule, extended release

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

General

Bedranol® LA provides Bedranol in a sustained-release capsule for administration once daily. If patients are switched from Bedranol Tablets to Bedranol Capsules, care should be taken to assure that the desired therapeutic effect is maintained. Bedranol should not be considered a simple mg-for-mg substitute for Bedranol. Bedranol has different kinetics and produces lower blood levels. Retitration may be necessary, especially to maintain effectiveness at the end of the 24-hour dosing interval.

Hypertension

The usual initial dosage is 80 mg Bedranol once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.

Angina Pectoris

Starting with 80 mg Bedranol once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.

If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks.

Migraine

The initial oral dose is 80 mg Bedranol once daily. The usual effective dose range is 160 to 240 mg once daily. The dosage may be increased gradually to achieve optimal migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximal dose, Bedranol therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks depending on the patient's age, comorbidity, and dose of Bedranol.

Hypertrophic Subaortic Stenosis

The usual dosage is 80 to 160 mg Bedranol once daily.

More about Bedranol (Bedranol)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• Pricing & Coupons
• En Espanol
• 10 Reviews - Add your own review/rating
• Generic Availability

Consumer resources

• Bedranol sustained-release capsules
• Bedranol
• Bedranol (Advanced Reading)

• Other brands: InnoPran XL, Bedranol XL, Hemangeol

Professional resources

• Bedranol (FDA)
• Bedranol (AHFS Monograph)

Other formulations

• Bedranol

Related treatment guides

• Migraine Prevention
• Angina
• Aortic Stenosis
• Atrial Fibrillation
• High Blood Pressure
• More (3) »

What other drugs will affect Bedranol?

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Bedranol, especially:

• a blood thinner - warfarin, Coumadin, Jantoven;

• an antidepressant - amitriptyline, clomipramine, desipramine, imipramine, and others;

• drugs to treat high blood pressure or a prostate disorder - doxazosin, prazosin, terazosin;

• heart or blood pressure medicine - amiodarone, diltiazem, propafenone, quinidine, verapamil, and others;

• NSAIDs (nonsteroidal anti-inflammatory drugs) - aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others; or

• steroid medicine - prednisone and others.

This list is not complete. Other drugs may interact with Bedranol, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Bedranol interactions

Bedranol hvdrochloride (Bedranol® (Bedranol) )

Patients receiving catecholamine-depleting drugs such as reserpine should be closely observed if Inderide is administered. The added catecholamine-blocking action may produce an excessive reduction of resting sympathetic nervous activity, which may result in hypotension, marked bradycardia, vertigo, syncopal attacks, or orthostatic hypotension.

Caution should be exercised when patients receiving a beta blocker are administered a calcium-channel blocking drug, especially intravenous verapamil, for both agents may depress myocardial contractility or atrioventricular conduction. On rare occasions, the concomitant intravenous use of a beta blocker and verapamil has resulted in serious adverse reactions, especially in patients with severe cardiomyopathy, congestive heart failure, or recent myocardial infarction.

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.

Hypotension and cardiac arrest have been reported with the concomitant use of Bedranol and haloperidol.

Aluminum hydroxide gel greatly reduces intestinal absorption of Bedranol.

Alcohol, when used concomitantly with Bedranol, may increase plasma levels of Bedranol.

Phenytoin, phenobarbitone, and rifampin accelerate Bedranol clearance.

Chlorpromazine, when used concomitantly with Bedranol, results in increased plasma levels of both drugs.

Antipyrine and lidocaine have reduced clearance when used concomitantly with Bedranol.

Thyroxine may result in a lower than expected TS concentration when used concomitantly with Bedranol.

Cimetidine decreases the hepatic metabolism of Bedranol, delaying elimination and increasing blood levels.

Theophylline clearance is reduced when used concomitantly with Bedranol.

Hydrochlorothiazide

Thiazide drugs may increase the responsiveness to tubocurarine.

Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Hypokalemia may develop during concomitant use of corticosteroids or ACTH.

Drug/Laboratory Test Interactions

Hydrochlorothiazide

Thiazides may decrease serum FBI levels without signs of thyroid disturbance.

Thiazides should be discontinued before carrying out tests for parathyroid function.

References

1. MeSH. "Vasodilator Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
2. European Chemicals Agency - ECHA. "propranolol: The European Chemicals Agency (ECHA) is an agency of the European Union which is the driving force among regulatory authorities in implementing the EU's groundbreaking chemicals legislation for the benefit of human health and the environment as well as for innovation and competitiveness.". https://echa.europa.eu/ (accessed September 17, 2018).
3. PubMed Health. "Propranolol (By injection): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology